Auteurs Bost F
Cell cycle (Georgetown, Tex.) Aug 2012
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.Auteurs Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S
PloS one Juil 2012
Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.Auteurs Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C
The Journal of biological chemistry Juil 2012
Proper macrophagic differentiation requires both autophagy and caspase activation.Auteurs Jacquel A, Obba S, Solary E, Auberger P
Autophagy Jul 2012
Differentiation of Human Adipose-Derived Stem Cells into « Brite » (Brown-in-White) Adipocytes.Auteurs Pisani DF, Djedaini M, Beranger GE, Elabd C, Scheideler M, Ailhaud G, Amri EZ
Frontiers in endocrinology Jun 2012
Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.Auteurs Fenouille N, Grosso S, Yunchao S, Mary D, Pontier-Bres R, Imbert V, Czerucka D, Caroli-Bosc FX, Peyron JF, Lagadec P
The Journal of pathology May 2012
Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.Auteurs Meynet O, Bénéteau M, Jacquin MA, Pradelli LA, Cornille A, Carles M, Ricci JE
Leukemia May 2012
PPARs: Interference with Warburg’ Effect and Clinical Anticancer Trials.Auteurs Vamecq J, Colet JM, Vanden Eynde JJ, Briand G, Porchet N, Rocchi S
PPAR research Mai 2012
Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.Auteurs Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R
Oncogene May 2012
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.Auteurs Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P
Oncotarget Apr 2012